SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001410578-23-002132
Filing Date
2023-09-29
Accepted
2023-09-29 08:01:40
Documents
53
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 6-K aktx-20230630x6k.htm   iXBRL 6-K 115611
2 EX-99.1 aktx-20230630xex99d1.htm   iXBRL EX-99.1 699448
3 EX-99.2 aktx-20230630xex99d2.htm EX-99.2 139797
4 EX-99.3 aktx-20230630xex99d3.htm EX-99.3 100938
  Complete submission text file 0001410578-23-002132.txt   5253942

Data Files

Seq Description Document Type Size
5 EX-101.SCH aktx-20230630.xsd EX-101.SCH 46905
6 EX-101.CAL aktx-20230630_cal.xml EX-101.CAL 32165
7 EX-101.DEF aktx-20230630_def.xml EX-101.DEF 340112
8 EX-101.LAB aktx-20230630_lab.xml EX-101.LAB 411758
9 EX-101.PRE aktx-20230630_pre.xml EX-101.PRE 380294
47 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20230630x6k_htm.xml XML 805035
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 6-K | Act: 34 | File No.: 001-36288 | Film No.: 231291938
SIC: 2834 Pharmaceutical Preparations